Skip to the content

LurexBio · Recognition engineering for immune-cold cancers

Fort Lauderdale, FL

info@lurexbio.com
  • Company
  • Platform
    • NeoTag™
    • Atraxis™
    • AegisCore™
    • StratIQ™
  • Science
  • Pipeline
  • IP
  • News & Media
  • Contact
  • Investors
Investors
  • Company
  • Platform
    • NeoTag™
    • Atraxis™
    • AegisCore™
    • StratIQ™
  • Science
  • Pipeline
  • IP
  • News & Media
  • Contact
  • Investors

Press Releases

06
Nov
A tumor cell carrying all four LurexBio platform layers
NewsPress Releases

Lurex Bio Announces Patent Filings and a New Frontier in Immune Engineering

Lurex Bio has filed multiple U.S. provisional patent applications covering its immune-signal and vesicle-based targeting systems, its first step toward international protection und

Read More
Share
  • Platform
  • Science
  • Pipeline
  • Intellectual Property
  • News & Media
  • Contact
1-855-LUREXBIO
info@lurexbio.com

Engineering recognition at the tumor surface.

Making tumors visible to the immune system.

LurexBio is a preclinical-stage biotechnology company. No efficacy or safety data exist to date. Platform descriptions represent design intentions and scientific hypotheses, not demonstrated results. Nothing on this site is an offer to sell, or a solicitation of an offer to buy, any securities. NeoTag™, Atraxis™, AegisCore™, and StratIQ™ are trademarks of LurexBio, Inc.

Contact us:
info@lurexbio.com
1-855-LUREXBIO
Our address:
501 East Las Olas Blvd., Suite 300, Fort Lauderdale, FL 33301
Follow us:
LinkedIn
Terms of Use
Privacy Policy
© 2026 LurexBio, Inc. All rights reserved.

A recognition engineering company advancing non-genetic, non-viral approaches for immune-cold cancers.

Latest news
  • Why start with immune recognition?October 17, 2026
  • Lurex Bio Announces Patent Filings and a New Frontier in Immune EngineeringNovember 6, 2025

All news

info@lurexbio.com